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of signiﬁcantly higher relapse in association with MICA
mismatches in 10/10 patients (HR 1.7, 95% CI 1.2-2.4, p¼
0.003) but not in 9/10 patients. There was a suggestion that
MICA mismatches were associated with a higher risk of
aGVHD grades II-IV (HR 1.4, 95% CI 1.1-1.9, p¼ 0.013) but not
grades III-IV and with higher risk of cGVHD (HR 1.8, 95% CI:
1.0-3.1, p value 0.04). There were no signiﬁcant interactions
between MICA mismatches and HLA matching (9/10 vs. 10/
10). There was also a suggestion of an association between
donor MICA-129 non-VV genotypes and slower platelet
engraftment with HR 1.4 (95% CI 1.109-1.985, p¼ 0.02).
Conclusions: In this cohort neither MICA-129 poly-
morphism nor MICA mismatches were associated with HSCT
outcomes at a level that reached the predetermined level of
statistical signiﬁcance. This registry analysis in patients with
ALL, AML and MDS was discordant with prior reports of
single center studies of patients with mixed diagnoses.Figure.188
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Background: Double cord blood transplantation (dCBT) is an
important strategy to overcome dose limitation of single CBT
and extend its availability to a broader range of patients (pts).
The dominance of one of the two CB units occurs as early as
12 days after dCBT, and by day 21, over 80% of transplanted
pts have single unit dominance maintaining long-term he-
matopoiesis. However, outcomes of pts who do not achieve
unit dominance, but rather persistence of both CB units after
dCBT is not known.
Methods: We retrospectively analyzed 105 pts with hema-
tological malignancies who engrafted after dCBT between
2003 through 2014 and investigated the presence of donor T
cell chimerism (TCC) of at least 10% from each CB unit at day
100 +/- 30 after transplant (dTCC). Only pts with progression
free survival at day 100 were evaluable.
Results: Of 105 pts, 10 (9.5%) had dTCC. Median age was 43
(range; 1e73). AMLwas themost commondiagnosis in 57.1% of
the pts followed by ALL in 21.9. Disease status was complete
remission (CR) in 67.6% and active disease in 32.4% of the pts.
Conditioningwasmyeloablative in 73.3% and reduced intensity
in 26.7% due to older age and/or frailty. Immunosuppressive
therapy included mycophenolate mofetil with tacrolimus, and
all pts received anti-thymocyte globulin as a part of the con-
ditioning regimen. Per protocol priority over the years, 72.4% of
the pts had ex-vivo expansion of one of the CB units in
mesenchymal stem cell co-culture. Final median dose of CD34+
and total nucleated cells infused were 0.36x106/kg (0.12-5.35)
and 0.51x107/kg (0.3-1.29) respectively.
Patient, disease and graft characteristics were very similar
between dTCC and single donor TCC (sTCC) pts. However,
compared to sTCC, dTCC pts had better 4/6 HLA matching
between 2 CB units (66.3% vs. 90%, p¼0.1) and less manip-
ulation of one of the CB units with expansion (74.7% vs. 50%,
p¼0.1).Median follow-up was 44.7 months (mo). Transplant out-
comes were similar between dTCC and sTCC pts with 3-year
(yr) overall survival and progression free survival of 40% vs.
41.4% and 40% vs. 32.3% respectively. Incidence of progression
was similar between dTCC and sTCC groups (28.9% vs. 27.6%).
Of 10 pts with dTCC, 3 died within 6 mo after dCBT without
repeat TCC and they were not evaluable for long-term assess-
ment. Among others, 1 pt had autologous recovery with pro-
gression after 6 mo of dCBT. Unit dominance with 100% TCC
was observed in 4 pts within 4 to 20 mo after dCBT; 1 of those
pts progressed 5 mo after unit dominance was established and
another pt died of fungal infection at 15 mo. However, 2 AML
pts showed long-term dTCC with units contributing 58%/42%
and 84%/16% at last evaluation, 4 and 3.2 years after dCBT. They
both remain in CR and free of progression.
Conclusion: The unique situation of TCC from both CB units
around day 100 is not associated with worse transplant
outcomes in pts receiving dCBT. These provocative results
need to be conﬁrmed in larger studies.189
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
especially in minorities & patients with acute leukemia &
lymphoma requiring urgent transplant. The extent that cord
blood (CB) extends transplant access, however, is not estab-
lished. Moreover, the contribution of the domestic U.S. &
international CB inventories to minority patients is an
important factor in public CB Bank funding considerations.
Methods:We prospectively analyzed the availability of 7-8/8
HLA-matched URDs or 4-6/6 HLA-A,-B antigen, -DRB1 allele
matched CB units in patients with hematologic malignancies
Table
Patient Ancestry 8/8 URD 7/8 URD dCB No 7-8/8 URD/dCB
Europeans
N[ 605
397/605 (66%) 97/605 (16%) 103/605 (17%) 8/605 (1%)
Non-Europeans
N[ 279
74/279 (26.5%) 55/279 (20%) 115/279 (41%) 35/279 (12.5%)
African (n ¼ 95) 10/95 (11%) 24/95 (25%) 37/95 (39%) 24/95 (25%)
White Hispanic (n ¼ 59) 16/59 (27%) 17/59 (29%) 19/59 (32%) 7/59 (12%)
Asian (n ¼ 66) 20/66 (30%) 8/66 (12%) 37/66 (56%) 1/66 (1%)
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given priority if available; otherwise HLA-mismatched URDs
or double-unit CB (dCB) grafts were chosen.
Results: Of 884 patients, 623 (70%) received a 7-8/8 URD
transplant, 218 (25%) underwent dCBT & 43 (5%) had no URD/
dCB graft. The distribution of 8/8 URD, 7/8 URD, dCB & no URD/
dCB grafts is shown (Table). The majority (66%) of Europeans
received an 8/8 URD whereas the majority of non-Europeans
received either a mismatched URD or dCB graft. 35/43 (81%) of
patients without URD/CB grafts had non-European origins, &
no URD/dCB grafts were seen in 1% of Europeans versus 12.5%
of non-Europeans. When non-Europeans were subdivided
into the largest minority groups we found African, White
Hispanic & Asian patients were very unlikely to have a
matched URD, were most likely to receive dCB grafts, &
African ancestry patients were the most likely (one quarter) to
have no URD or dCB graft. Interestingly, there was no
difference in 8 allele donor recipient HLA-match grade of
European (median 5/8, range 2/8-8/8) & non-European
(median 5/8, range 1/8-8/8) dCBT recipients. When the origin
of dCB grafts was analyzed we found that overall 71% of units
for European ancestry patients were domestic as compared to
78% of units for non-Europeans. However, in African & white
Hispanic patients 86% & 83% of CB units were obtained from
the domestic inventory, respectively.
Conclusion: CB extends transplant access to all patients & is
especially important for minorities who are unlikely to have
a matched URD. The fact that over 80% of units used in Af-
rican & white Hispanic patients were domestic, that these
patients will be very unlikely to identify a matched URD
regardless of the size of the global volunteer donor registry, &
that some minority patients do not have suitable CB grafts
emphasizes the critical importance of the funding of US
public CB banks.190
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A major challenge in unrelated hematopoietic cell trans-
plantation (HCT) is the prediction of permissive HLA mis-
matches, i.e. those associated with lower clinical risks
compared to their non-permissive counterparts. For HLA-
DPB1, a clinically prognostic model has been shown to be
matching for T-cell epitope (TCE) groups assigned by cross-
reactivity of T-cells alloreactive to HLA-DPB1*09:01, however
the molecular basis of this observation is not fullyunderstood. Here we have mutated amino acids (aa) in 10
positions of HLA-DPB1*09:01 to other naturally occurring
variants, expressed them by lentiviral vectors in B cell lines
and quantitatively measured allorecognition by 17 CD4+ T-
cell effectors from 6 unrelated individuals. A signiﬁcant
impact on the median alloresponse was observed for peptide
contact positions 9, 11, 35, 55, 69, 76 and 84, but not for
positions 8, 56 and 57 pointing away from the groove. A score
for the “functional distance” (FD) from HLA-DPB1*09:01 was
deﬁned as the sum of the median impact of polymorphic aa
in a given HLA-DPB1 allele on T-cell alloreactivity. Estab-
lished TCE group assignment of 23 alleles correlated with FD
scores of 0.5, 0.6-1.9 and 2 for TCE groups 1, 2 and 3,
respectively. Based on this, prediction of TCE group assign-
ment will be possible for any given HLA-DPB1 allele. In silico
TCE group classiﬁcation was performed for currently 328
HLA-DPB1 alleles encoding distinct proteins for which T-cell
crossreactivity patterns are unknown, with subsequent
functional conﬁrmation for 7/7 of them. These ﬁndings have
practical implications for the applicability of TCE group
matching in unrelated HCT, and provide new insights into
the molecular mechanisms underlying this model. The
innovative concept of FD opens new potential avenues for
risk prediction in unrelated HCT.191
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Topic Signiﬁcance & Study Purpose/Background/Ratio-
nale: HLA haploidentical stem cell transplantation (SCT)
has expanded donor sources from family members. Never-
theless, some patients have no donor candidate and no time
to select a suitable donor, especially in post-transplant
relapse or rejection. In kidney or liver transplantation, on the
other hand, spousal transplant has been routinely per-
formed. In this study, we presented six cases of spousal SCT
for post-transplant relapse/rejection, and discussed the
possibility of spousal SCT.
Methods, Intervention, & Analysis: Six patients (M/F 4/2,
25-53 years old) underwent SCT from their spouse at Hyogo
College of Medicine between October 2008 and November
2013permissionof IRB.Original diseaseswereacute leukemia
(AML 2, ALL 2, MLL 1) and one case of NHL. All patients
received a third SCT for post-transplant relapse except for one
undergoing SCT for graft rejection after unrelated SCT. HLA
disparity in GVH/HVG directions were 2/4, 3/3, 2/2, 5/6, 2/1,
and 3/3 antigens in HLA A, B, DR. The conditioning regimen
consisted of FLU/MEL/ATG with or without 3 Gy of TBI for
relapse cases, and ATG plus 4 Gy of TBI for the rejection case.
